The first five patients in the US who received their cannabis medicine from the federal government were featured speakers at the National Organization for the Reform of Marijuana Laws’ (NORML) annual conference held in Washington, DC in 1990. A member of the Board made a call to a friend at C-Span, the local civic orientated TV channel that is broadcast nationwide, suggesting this conference was worthy of its attention. They agreed and broadcast the entire conference live and repeated the entire program on several occasions.
Forty thousand phone calls poured into the NORML offices that month. The patients had put a new face on marijuana. These were not the stoner hippies stereotype so often portrayed in the press, but men and women with gray hair, soft words and serious illnesses. They were everybody’s dad, grandmother or son and the US government provided them with their medicine. The callers were from all over the country, supportive, and wanted to know more about “medical marijuana.”
After working together informally for a few years, the five federal patients and health care professionals with expertise in clinical cannabis applications, formalized their work by incorporating as Patients Out of Time, co-founded in the spring of 1995 by Mary Lynn Mathre and Al Byrne, previously members of the NORML Board of Directors. The organization’s mission was and is to educate health care professionals and the public about therapeutic cannabis.
To execute the mission the organization decided to approach national professional organizations that were health care focused or had national significance in related fields. Individual MD’s, RN’s and other professionals we had all dealt with over the years were almost universally supportive of medical cannabis but only in private. To overcome the obvious intimidation that had infiltrated medical conversation of individuals publicly, we concluded that a professional organization, taking a supportive stand, would offer personal protection to each member and grant the issue the prestige of the organization.
Mary Lynn Mathre had made the first such presentation to the Virginia Nurses Association in 1994 and they passed a Resolution in support of medical cannabis, the first nursing organization to do so. Over the years the list of support groups has grown to dozens. It includes the oldest and largest health care organization in the US, The American Public Health Association; the American Nurses Association; thirteen state nursing associations; and the Institute of Medicine.
To maximize our educational effort we created tools for other patient advocates to utilize. Our first project was to produce, Marijuana as Medicine, an eighteen-minute award winning video (US and Canada) that has been viewed thousand of times in over 20 countries. This video again reinforced the true image of the patients as everyday folks who were ill and used cannabis successfully as medicine. In their own words they told their stories of sickness, prescription drugs, operations, depression, oncoming blindness, and then the reversal of all those negatives when they started on a protocol of therapeutic cannabis.
The second tool was Cannabis in Medical Practice: A Legal, Historical and Pharmacological Overview of the Therapeutic Use of Marijuana, edited by Mathre and contributed to by seventeen experts from Brazil, The Netherlands, Jamaica and the United States. This book was created to answer the questions that were being asked by hundreds of patients, to assist their caregivers in understanding the full spectrum of therapeutic cannabis use and to provide hundreds of references should the reader wish to learn more. It has become a classic in its field and continues to be referenced.
By the end of the nineties the awakening provided by C-Span had blossomed into a full-scale awareness that the US government policy on medical cannabis was at best, misguided. To us it seemed just plain mean, based on a relentless propaganda machine that just lied about the issue. The public seemed to agree. Over the decades polls about medical cannabis efficacy and medical necessity climbed from the low 40’s to the mid 70’s, even into the 80 percentile in some states.
In order for research to be considered of merit it must be replicated and peer reviewed. The results must be made public, scrutinized, and validated. To overcome any federal government dialog that indicated that such research did not exist we started a series of clinical cannabis conferences beginning in 2000.
The first such meeting was sponsored by the College of Nursing and the College of Medicine of the University of Iowa. This sponsorship was critical to our work. It enabled the agenda to be accredited for professional education for MDs, RNs, SWs, JDs and other professionals. To be so honored the faculty and the presentations had to meet the highest of academic standards. All conferences in the series have received this accredited status. The entire conference was broadcast live to various locations including McGill University in Canada and to the health education network of the State of Oregon. The faculty was of the highest quality; the press response supportive and the studies were presented under the theme of Science Based Clinical Applications – this formed a benchmark of knowledge from which there has been no retreat.
Our second conference was sponsored by the Health Department of the State of Oregon, the Oregon Nurses Association and other groups. The faculty included a number of speakers from European countries and we involved the hemp community in the proceedings by discussing the positive impact on health that cannabis used as food, hemp, proffered for sick and well alike. The main focus of this forum was to discuss pain of all types, since over 70% of the Oregon patients reported pain relief as their primary purpose for the use of cannabis.
The Third National Clinical Conference on Cannabis Therapeutics was held in May of 2004 in Charlottesville, VA. It was co-sponsored by the Virginia Nurses Association, the Pain Management Center and the Medical, Law and Nursing Schools of the University of Virginia, known in the US for its conservative ways. The faculty included the world’s finest cannabis researchers, clinicians, patients and caregivers from the US, England, Israel, and Canada. At this venue cannabis use as medicine ranged from the therapeutic use by infants and children to use with Hospice patients.
Our Board of Directors includes the four US federal cannabis patients left alive. In the spring of 2001 in Missoula, MT, four federal patients underwent an extensive three-day examination of every system in their body to determine the long-term effects of cannabis. Known widely as The Missoula Chronic Use Study, the investigators concluded that after using cannabis therapeutically for a range of 11 to 27 years, with a dose of nine cured ounces per month for three and eleven cured ounces every 26 days for one, they were all in fine condition exempting their original illness and the wear and tear of age. A thorough review of the study, Chronic Cannabis Use in the Compassionate Investigational New Drug Program: An Examination of Benefits and Adverse Effects of Legal Clinical Cannabis was published in the Journal of Cannabis Therapeutics and is available for review online at www.medicalcannabis.com.
We worked on the Petition to Reschedule Cannabis that was submitted to and forwarded by the US Drug Enforcement Administration (DEA) to the US Department of Health and Human Services (HHS). The petition, presented as required by government regulations, requested a complete review of all existing literature and research by HHS concerning medical cannabis with the purpose of having cannabis rescheduled to a minimum of schedule three (“off label” prescription level) or less. The complete document is available at www.drugscience.org. Under US law a finding by HHS that cannabis has medical use would require the DEA to reschedule cannabis. Advocates for medical cannabis in the US requested their elected representatives to press for an expedited review. This request was denied in 2012.
Our official policy statement is clear: “Patients Out of Time has no other interest, nor does the organization have any opinion, stated or unstated, about any issue other than therapeutic cannabis.” No one is confused about whom we represent or what we want and the federal government has found that disarming. No member of the federal government has ever risen to our call to debate us. The reason is obvious. They can call us no name except “patient advocates” and we would win.
The Fourth National Clinical Conference on Cannabis Therapeutics was held in Santa Barbara, California hosted by the Santa Barbara City College. The University of California San Francisco’s Accreditation and Educational Development Office of Continuing Medical Education accredited the forum for physician participation and the California Nurses Association provided Continuing Education Units (CEU’s) to the nursing community. Held and co-sponsored by Patients Out of Time on April 6-8, 2006 the theme of the conference was: The Body-Mind Connection. While various aspects of clinical use was covered, the core of the forum involved both physical cannabis treatment and the use of cannabis for PTS(d), ADD, depression and other emotional or psychological problems. There were many moments over the week end that were memorable. Santa Barbara’s mayor opened the forum advising all pay close attention to the speakers wisdom and “to go forth and multiply.” Discussion of cannabis use by infants, by Vets, by AIDS patients, for Canadian pain patients were echoed during the breaks. Comedian Rodney Dangerfield’s wife Joan gave a funny and poignant talk about her husbands life long “love affair with cannabis.” Jay Leno provided a video of an his interview on the subject with Mr. Dangerfield. A disappointment was the presentation of Montel Williams, talk show host.
He informed the professional audience that science was not the answer to cannabis prohibition, he was.
We were back to Pacific Grove, California in 2008 with the theme of Cannabis: Re-entering Mainstream Medicine. Again the California Nurses Association and the U. of CA School of Medicine San Francisco were our co-sponsors. A highlight was a “press moment”. Three federal patients opened their government sealed cans of federal cannabis in front on dozens of press cameras. Opened, they revealed pre-rolled cannabis cigarettes, about 300 per can, full of seeds and stems. The same as we had found in 2001 during “The Missoula Study.” The theme was right on the future, by 2013 DC and 20 states had made cannabis a medicine.
April 16-17, 2010 in Warwick, RI Patients Out of Time with co-sponsors the Rhode Island Nurses Association and the San Francisco School of Medicine held The Sixth National Conference on Cannabis Therapeutics declaring as its theme that the statement Cannabis: The Medicine Plant was very true. The Faculty was stunning in its academic research and diversity of interest. Cannabis and alcohol use discussed by a PhD from local Brown University; cannabis for Alzheimer’s disease and osteoarthritis was presented by the “Grandfather of Cannabis Medicine” Dr. Raphael Mechoulam, Hebrew University, Jerusalem; two PhD scientists from Brazil spoke to cannabis and PTS(d) and other psychiatric uses, emphasizing cannabis does not cause or exacerbate schizophrenia; numerous patients backed by primary care physicians spoke of use for seizures, spasticity, pain, addiction relief and more.
Tucson, AZ was the location of The Seventh National Clinical Conference on Cannabis Therapeutics with the San Francisco School of Medicine’s Continuing Medical Education Office providing CME’s and the University of AZ College of Nursing the CEU’s. Patients Out of Time was joined by Dr. Andy Weil’s Arizona Center for Integrative Medicine of the College of Medicine, U. of AZ. Mainstream and integrative medicine – cannabis has come a long way despite the federal government’s persecution of the cannabis plant. We featured The Endocannabinoid System: Clinical Implications for Health Care as the theme. Presentations on phytocannabinoids in the treatment of breast cancer and Glioma cell cancer sparked a lot of interest; as did use for skin cancer and eye disease; for use with glaucoma; as an “exit drug”; for addiction relief; for TBI and PTS among Veterans; for the control of Alzheimer’s disease.
We have changed the media face of a cannabis patient in the United States forever by presenting a dignified, composed and articulate cast of patients. We have elevated the level of discourse about therapeutic cannabis through the education of health care professionals and their organizations and associations. We will not give up or grow weary of making therapeutic cannabis available for all patients. We can’t, we are Patients Out of Time.
Al Byrne for Patients Out of Time.